New Research Areas

In conclusion, it is clear that we have come a long way in the more than 60 years since serendipity led to the observation that amphetamine can reduce symptoms in hyperkinetic children. We now have a clear understanding of ADHD as a bona fide disorder, have interesting animal paradigms to model aspects of ADHD, have diagnostic criteria for adolescents, and have therapies that successfully treat the majority of patients, albeit with some limiting side effects. Ongoing research and future directions are clearly going to enhance our ability to understand, diagnose, and treat ADHD successfully in all populations. One promising new molecular target is the histamine H3 receptor, where inverse agonists have shown some efficacy in animal models of ADHD.96

References

1. Chung, B.; Suzuki, A. R.; McGough, J. J. Exp. Opin. Emerg. Drugs 2002, 7, 269-276.

2. Biederman, J. Biol. Psychiatry 2005, 57, 1215-1220.

3. AAP Clinical practice guideline. Pediatrics 2000, 105, 1158-1170.

4. Swanson, J. M.; Sergeant, J. A.; Taylor, E.; Sonuga-Barke, E. J.; Jensen, P S.; Cantwell, D. P. Lancet 1998, 351, 429-433.

5. Rohde, L. A.; Biederman, J.; Busnello, E. A.; Zimmermann, H.; Schmitz, M.; Martins, S.; Tramontina, S. J. Am. Acad. ChildAdolesc. Psychiatry 1999, 38, 716-722.

6. McGough, J. J.; Barkley, R. A. Am. J. Psychiatry 2004, 161, 1948-1956.

7. Gallagher, R.; Blader, J. Ann. NY Acad. Sci. 2001, 931, 148-171.

8. Evans, S. W.; Pelham, W E.; Smith, B. H.; Bukstein, O.; Gnagy, E. M.; Greiner, A. R.; Altenderfer, L.; Baron-Myak, C. Exp. Clin. Psychopharmaccol. 2001, 9, 163-175.

9. Epstein, J. N.; Johnson, D. E.; Varia, I. M.; Conners, C. K. J. Clin. Exp. Neuropsychol. 2001, 23, 362-371.

10. Monastra, V J.; Lubar, J. F; Linden, M. Neuropsychology 2001, 15, 136-144.

11. Faraone, S. V; Biederman, J. Biol. Psychiatry 1998, 44, 951-958.

12. Greenhill, L. L.; Pliszka, S.; Dulcan, M. K.; Bernet, W; Arnold, V; Beitchman, J.; Benson, R. S.; Bukstein, O.; Kinlan, J.; Mcclellan, J. et al. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41, 26S-49S.

13. McGough, J. J. Biol. Psychiatry 2005, 57, 1367-1373.

14. Todd, R. D.; Lobos, E. A.; Sun, L. W; Neuman, R. J. Mol. Psychiatry 2003, 8, 103-108.

15. Bark, C.; Bellinger, F P; Kaushal, A.; Mathews, J. R.; Partridge, L. D.; Wilson, M. C. J. Neurosci. 2004, 24, 8796-8805.

16. Brophy, K.; Hawi, Z.; Kirley, A.; Fitzgerald, M.; Gill, M. Mol. Psychiatry 2002, 7, 913-917.

17. Barr, C. L.; Feng, Y; Wigg, K.; Bloom, S.; Roberts, W; Malone, M.; Schachar, R.; Tannock, R.; Kennedy, J. L. Mol. Psychiatry 2000, 5, 405-409.

18. Russell, V A.; Sagvolden, T; Johansen, E. B. Behav. Brain Funct. 2005, 1, 9.

19. Heiser, P.; Friedel, S.; Dempfle, A.; Konrad, K.; Smidt, J.; Grabarkiewicz, J.; Herpertz-Dahlmann, B.; Remschmidt, H.; Hebebrand, J. Neurosci. Biobehav. Rev. 2004, 28, 625-641.

20. Bush, G.; Valera, E. M.; Seidman, L. J. Biol. Psychiatry 2005, 57, 1273-1284.

21. Sagvolden, T. Neurosci. Biobehav. Rev. 2000, 24, 31-39.

22. Fox, G. B.; Pan, J. B.; Esbenshade, T A.; Bennani, Y L.; Black, L. A.; Faghih, R.; Hancock, A. A.; Decker, M. W Behav Brain Res. 2002, 131, 151-161.

23. Robbins, T W Psychopharmacology (Berl.) 2002, 163, 362-380.

24. Taffe, M. A.; Davis, S. A.; Yuan, J.; Schroeder, R.; Hatzidimitriou, G.; Parsons, L. H.; Ricaurte, G. A.; Gold, L. H. Neuropsychopharmacology 2002, 27, 993-1005.

25. Bizarro, L.; Stolerman, I. P. Psychopharmacology (Berl.) 2003, 170, 271-277.

26. Fox, G. B.; Esbenshade, T. A.; Pan, J. B.; Radek, R. J.; Krueger, K. M.; Yao, B. B.; Browman, K. E.; Buckley, M. J.; Ballard, M. E.; Komater, V A. et al. J. Pharmacol. Exp. Ther. 2005, 313, 176-190.

27. Sagvolden, T.; Russell, V A.; Aase, H.; Johansen, E. B.; Farshbaf, M. Biol. Psychiatry 2005, 57, 1239-1247.

28. De Bruin, N. M.; Kiliaan, A. J.; De Wilde, M. C.; Broersen, L. M. Neurobiol. Learn. Mem. 2003, 80, 63-79.

29. Prediger, R. D.; Pamplona, F A.; Fernandes, D.; Takahashi, R. N. Int. J. Neuropsychopharmacol. 2005, 1-12.

30. Terry, A. V, Jr.; Hernandez, C. M.; Buccafusco, J. J.; Gattu, M. Neuroscience 2000, 101, 357-368.

31. Nakamura-Palacios, E. M.; Caldas, C. K.; Fiorini, A.; Chagas, K. D.; Chagas, K. N.; Vasquez, E. C. Behav. Brain Res. 1996, 74, 217-227.

32. Hernandez, C. M.; Hoifodt, H.; Terry, A. V, Jr. J. Psychiatry Neurosci. 2003, 28, 197-209.

33. Ueno, K. I.; Togashi, H.; Mori, K.; Matsumoto, M.; Ohashi, S.; Hoshino, A.; Fujita, T.; Saito, H.; Minami, M.; Yoshioka, M. Behav. Pharmacol. 2002, 13, 1-13.

34. Jentsch, J. D. Behav. Brain Res. 2005, 157, 323-330.

35. Sagvolden, T.; Metzger, M. A.; Schiorbeck, H. K.; Rugland, A. L.; Spinnangr, I.; Sagvolden, G. Behav. Neural Biol. 1992, 58, 103-112.

36. Wilens, T. E.; Biederman, J.; Spencer, T J.; Bostic, J.; Prince, J.; Monuteaux, M. C.; Soriano, J.; Fine, C.; Abrams, A.; Rater, M. et al. Am. J. Psychiatry 1999, 156, 1931-1937.

37. Pataki, C. S.; Feinberg, D. T.; McGough, J. J. Exp. Opin. Emerg. Drugs 2004, 9, 293-302.

38. Levin, E. D.; Conners, C. K.; Silva, D.; Canu, W; March, J. Exp. Clin. Psychopharmacol. 2001, 9, 83-90.

39. Ueno, K.; Togashi, H.; Matsumoto, M.; Ohashi, S.; Saito, H.; Yoshioka, M. J. Pharmacol. Exp. Ther. 2002, 302, 95-100.

40. Myers, M. M.; Whittemore, S. R.; Hendley, E. D. Brain Res. 1981, 220, 325-338.

41. Gattu, M.; Terry, A. V, Jr.; Pauly, J. R.; Buccafusco, J. J. Brain Res. 1997, 771, 104-114.

42. Jones, S. R.; Gainetdinov, R. R.; Jaber, M.; Giros, B.; Wightman, R. M. et al. Proc. Natl. Acad. Sci. USA 1998, 95, 4029-4034.

43. Gainetdinov, R. R.; Wetsel, W C.; Jones, S. R.; Levin, E. D.; Jaber, M.; Caron, M. G. Science 1999, 283, 397-401.

44. Thakker, D. R.; Natt, F; Husken, D.; Maier, R.; Muller, M.; Van Der Putten, H.; Hoyer, D.; Cryan, J. F Proc. Natl. Acad. Sci. USA 2004, 101, 17270-17275.

45. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Nature 1996, 379, 606-612.

46. Biederman, J.; Spencer, T.; Wilens, T. Int. J. Neuropsychopharmacol. 2004, 7, 77-97.

47. Gainetdinov, R. R.; Jones, S. R.; Fumagalli, F; Wightman, R. M.; Caron, M. G. Brain Res. Brain Res. Rev. 1998, 26, 148-153.

48. Jaber, M.; Dumartin, B.; Sagne, C.; Haycock, J. W; Roubert, C. et al. Eur. J. Neurosci. 1999, 11, 3499-3511.

49. Davids, E.; Zhang, K.; Tarazi, F I.; Baldessarini, R. J. Brain Res. Brain Res. Rev. 2003, 42, 1-21.

50. Krause, K. H.; Dresel, S. H.; Krause, J.; Kung, H. F; Tatsch, K. Neurosci. Lett. 2000, 285, 107-110.

51. Volkow, N. D.; Wang, G. J.; Fowler, J. S.; Logan, J.; Franceschi, D.; Maynard, L.; Ding, Y. S.; Gatley, S. J.; Gifford, A.; Zhu, W. et al. Synapse 2002, 43, 181-187.

52. Hess, E. J.; Jinnah, H. A.; Kozak, C. A.; Wilson, M. C. J. Neurosci. 1992, 12, 2865-2874.

53. Hess, E. J.; Collins, K. A.; Copeland, N. G.; Jenkins, N. A.; Wilson, M. C. Genomics 1994, 21, 257-261.

54. Wilson, M. C. Neurosci. Biobehav. Rev. 2000, 24, 51-57.

55. Hess, E. J.; Collins, K. A.; Wilson, M. C. J. Neurosci. 1996, 16, 3104-3111.

56. Raber, J.; Mehta, P. P.; Kreifeldt, M.; Parsons, L. H.; Weiss, F; Bloom, F E.; Wilson, M. C. J. Neurochem. 1997, 68, 176-186.

57. Steffensen, S. C.; Wilson, M. C.; Henriksen, S. J. Synapse 1996, 22, 281-289.

58. Roberts, L. A.; Morris, B. J.; O'Shaughnessy, C. T Neuroreport. 1998, 9, 33-36.

59. Hou, Q.; Gao, X.; Zhang, X.; Kong, L.; Wang, X.; Bian, W; Tu, Y; Jin, M.; Zhao, G.; Li, B. et al. Eur. J. Neurosci. 2004, 20, 1593-1603.

60. Mill, J.; Curran, S.; Kent, L.; Gould, A.; Huckett, L.; Richards, S.; Taylor, E.; Asherson, P. Am. J. Med. Genet. 2002, 114, 269-271.

61. Mill, J.; Richards, S.; Knight, J.; Curran, S.; Taylor, E.; Asherson, P. Mol. Psychiatry 2004, 9, 801-810.

62. Zhang, K.; Tarazi, F I.; Baldessarini, R. J. Neuropsychopharmacology 2001, 25, 624-632.

63. Zhang, K.; Davids, E.; Tarazi, F I.; Baldessarini, R. J. Brain Res. Dev. Brain Res. 2002, 137, 135-138.

64. Davids, E.; Zhang, K.; Tarazi, F I.; Baldessarini, R. J. Psychopharmacology (Berl.) 2002, 160, 92-98.

65. Wolraich, M. L.; Wibbelsman, C. J.; Brown, T E.; Evans, S. W; Gotlieb, E. M.; Knight, J. R.; Ross, E. C.; Shubiner, H. H.; Wender, E. H.; Wilens, T Pediatrics 2005, 115, 1734-1746.

66. Moran-Gates, T; Zhang, K.; Baldessarini, R. J.; Tarazi, F I. Int. J. Neuropsychopharmacol. 2005, 8, 439-444.

67. Joyce, J. N.; Frohna, P A.; Neal-Beliveau, B. S. Neurosci. Biobehav. Rev. 1996, 20, 453-486.

68. Zhang, K.; Tarazi, F I.; Davids, E.; Baldessarini, R. J. Neuropsychopharmacology 2002, 26, 625-633.

69. Zhang, K.; Davids, E.; Tarazi, F I.; Baldessarini, R. J. Psychopharmacology (Berl.) 2002, 161, 100-106.

70. Avale, M. E.; Falzone, T L.; Gelman, D. M.; Low, M. J.; Grandy, D. K.; Rubinstein, M. Mol. Psychiatry 2004, 9, 718-726.

71. Dalley, J. W; Cardinal, R. N.; Robbins, T W Neurosci. Biobehav. Rev. 2004, 28, 771-784.

72. Chudasama, Y; Nathwani, F.; Robbins, T. W Behav. Brain Res. 2005, 158, 97-107.

73. Puumala, T; Ruotsalainen, S.; Jakala, P; Koivisto, E.; Riekkinen, P., Jr.; Sirvio, J. Neurobiol. Learn. Mem. 1996, 66, 198-211.

74. Granon, S.; Passetti, F; Thomas, K. L.; Dalley, J. W; Everitt, B. J.; Robbins, TU Neurosci. 2000, 20, 1208-1215.

75 . Pelham, W; Milich, R. Individual Differences in Response to Ritalin in Classwork. In Ritalin: Theory and Patient Management; Greenhill, L. , Osman, B. P, Eds.; Mary Ann Liebert: New York, 1991; pp 203-221.

76. AAP Clinical practice guideline. Pediatrics 2001, 108, 1033-1044.

77. Wee, S.; Woolverton, W L. Drug Alcohol Depend 2004, 75, 271-276.

78. Michelson, D.; Adler, L.; Spencer, T; Reimherr, F W; West, S. A.; Allen, A. J.; Kelsey, D.; Wernicke, J.; Dietrich, A.; Milton, D. Biol. Psychiatry 2003, 53, 112-120.

79. Creighton, C. J.; Ramabadran, K.; Ciccone, P E.; Liu, J.; Orsini, M. J.; Reitz, A. B. Bioorg. Med. Chem. Lett. 2004, 14, 4083-4085.

80. Biederman, J.; Spencer, T J. Attent. Disordt 2002, 6, S101-S107.

81. Garland, E. J. J. Psychopharmacol. 1998, 12, 385-395.

82. Patrick, K. S.; Markowitz, J. D. Hum. Psychopharm. 1997, 12, 527-546.

83. Biederman, J.; Spencer, T Pharmacotherapy of Attention Deficit Hyperactivity Disorder: Nonstimulant Treatments. In N1H Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder; Jensen, PS.; Cooper, J. R.; Elliot, J. M., Eds.; National Institutes of Health: Bethesda, MD, 1998, pp 97-104.

84. Thai, D. L.; Sapko, M. T; Reiter, C. T.; Bierer, D. E.; Perel, J. M. J. Med. Chem. 1998, 41, 591-601.

85. Michelson, D.; Allen, A. J.; Busner, J.; Casat, C.; Dunn, D.; Kratochvil, C.; Newcorn, J.; Sallee, F R.; Sangal, R. B.; Saylor, K. et al. Am. J. Psychiatry 2002, 159, 1896-1901.

86. Biederman, J.; Spencer, T Biol. Psychiatry 1999, 46, 1234-1242.

87. Gehlert, D. R.; Schober, D. A.; Gackenheimer, S. L. J. Neurochem. 1995, 64, 2792-2800.

88. Shaw, J.; Threlkeld, P; Wong, D. T Soc. Neurosci 1999, 25, 1963.

89. Mignot, E.; Renaud, A.; Nishino, S.; Arrigoni, J.; Guilleminault, C.; Dement, W C. Psychopharmacology (Berl.) 1993, 113, 76-82.

90. Labrid, C.; Moleyre, J.; Poignant, J. C.; Malen, C.; Mocaer, E.; Kamoun, A. Clin. Neuropharmacol. 1988, 11, S21-S31.

91. Hedges, D.; Reimherr, F W; Rogers, A.; Strong, R.; Wender, P. H. Psychopharmacol. Bull. 1995, 31, 779-783.

92. Connor, D. F; Fletcher, K. E.; Swanson, J. M. J. Am. Acad. Child Adolesc. Psychiatry 1999, 38, 1551-1559.

93. Arnsten, A. F; Steere, J. C.; Hunt, R. D. Arch. Gen. Psychiatry 1996, 53, 448-455.

94. Zametkin, J.; Ernst, M. N. Engl. J. Med. 1999, 340, 40-46.

95. Adult Self-Report Scale (ASRS), developed in conjunction with the World Health Organization. http://www.med.nyu.edu/psych/assets/ adhdscreener.pdf.

96. Esbenshade, T. A.; Fox, G. B.; Cowart, M. D. Mol. Interv. 2006, 6, 77-88.

Biographies

Kaitlin E Browman received her BA (with honors) from the Department of Psychology at the University of California, Santa Cruz (US) in 1992. She then pursued her doctoral degree at the University of Michigan (US) in the Department of Biopsychology under the tutelage of Dr Terry Robinson. While pursuing her PhD, Kaitlin focused on environmental factors influencing the development of locomotor sensitization to the psychomotor stimulants amphetamine and cocaine. After receiving her doctoral degree in 1998, Kaitlin completed her postdoctoral work in the laboratory of Dr John Crabbe at Oregon Health Sciences University in Portland, OR (US). As a postdoctoral fellow, Kaitlin expanded her scientific knowledge by studying the behavioral genetics of alcoholism. From Oregon Health Sciences University Kaitlin joined discovery efforts at Bristol-Myers Squibb in Wallingford, CT, in 2000, where she worked on the development of animal models of affective disorders, novel therapeutics, and genomic approaches to drug discovery. Currently Kaitlin is at Abbott Laboratories in North Chicago, IL, working on animal models of cognition, and supporting discovery projects focused on ADHD, Alzheimer's disease, or cognitive deficits associated with schizophrenia.

Gerard B Fox received his BSc (Hons) from the Department of Pharmacology, University College, Dublin (Ireland) in 1989. He then joined the Discovery Biology Team at Pfizer Central Research, Sandwich, Kent (UK) where he spent almost 4 years developing animal models of stroke and contributing to the drug discovery process. Gerard returned to Dublin to assume dual responsibilities as a neuroscientist with the biotechnology company, American Biogenetic Sciences, Inc., while completing his PhD in neuropharmacology at University College. During this time, Gerard also served as special lecturer in Advanced CNS Pharmacology. Subsequently, a postdoctoral fellowship at Georgetown University Medical Center, Washington, DC (USA) allowed Gerard to extend his expertise in behavioral neuroscience, neuroplasticity, as well as biomedical imaging, before joining the Global Pharmaceutical R&D division at Abbott Laboratories, Chicago, IL (US) in 1998. He is currently focused on discovering new drug treatments for CNS disorders such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, and cognitive dysfunction associated with schizophrenia or following brain injury. Gerard is author of more than 55 peer-reviewed articles and book chapters.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 117-138

The ADHD Success Formula

The ADHD Success Formula

This is an audio and guide that will help you battle through ADHD and Accomplish Twice As Much In Half The Time. Learn more by download your very own copy today.

Get My Free Ebook


Post a comment